anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

130,441-130,500 of 319,975

filter-aware
113
The slide is a reproduction of a scientific poster (Gevers et al., 2024) used as evidence for clinical trial outcomes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
114
The red box highlights the specific data point (Week 0 to Week 13) where the pooling occurs.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
115
The slide uses a red box and annotations to highlight the drop in sample size (n=125 to n=103) at week 13, suggesting data manipulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
116
The slide uses a red box and arrow to draw attention to the increase in HbA1c between week 0 and week 13.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
117
The slide uses a line chart with error bars to argue that the mean value hides adverse patient outcomes. It highlights the 1-standard deviation range and extrapolates to 2-standard deviations.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
118
The slide explicitly notes the re-graphing of data from a previous page to improve numerical accuracy on the time axis and clarity of standard deviation ranges.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
119
The slide uses a red box to highlight the specific comparison between placebo and pooled data at week 13.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
120
The slide uses a red box to highlight the specific data columns that demonstrate the increase in pre-T2D and T2D patient populations.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
121
The slide uses a direct quote from a medical paper to highlight a discrepancy between the company's claim and the reported data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
122
The slide uses red arrows and dots to visually demonstrate the discrepancy between cited data and the actual study graph.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
123
The slide uses a scatter plot with a linear regression line to refute a specific company claim regarding metabolic safety.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
124
The slide uses a red box to highlight the specific claim about 60% of participants having PD/DM at baseline.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
125
The slide uses a red oval to highlight the baseline data point and a dashed red box to represent the pre-T2D threshold range.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
126
The slide uses a direct quote from a conference abstract to highlight a discrepancy between the reported 60% figure and the author's own analysis.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
127
The slide uses a red box to highlight specific text in the source material to support the claim of burying data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
128
The slide highlights a 'cut-and-paste' error where the visual structure of the graph is identical between two sources, but the underlying data points (HbA1c values) have been altered.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
129
The slide uses visual annotations (red arrows and brackets) to highlight data manipulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
130
The slide uses a line chart with error bars to compare 'Original Data' vs 'New Data' to highlight data manipulation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
131
Uses a 'before-after' comparison to highlight data inconsistency as evidence of fraud.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
132
The slide uses a line chart to demonstrate that the fasting glucose values are identical to a previous study (Miller et al 2024), implying the new HbA1c claims are fabricated.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
133
The slide highlights that GH induces insulin resistance while DCCR blocks insulin release, creating a synergistic risk for hyperglycemia.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
134
The slide uses a direct quote and an abstract excerpt to build credibility for the argument that GH therapy has negative metabolic consequences.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
135
The slide uses direct excerpts from the FDA label to contrast with the company's reported clinical findings.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
136
The slide uses a 'two-hit' metaphor to describe the synergistic risk of the two medications.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
137
Soleno Therapeutics (SLNO)Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
138
The slide uses a list of 6 risk factors to build a medical case for why the drug's side effects are particularly dangerous for this specific patient group.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
139
The slide uses a combination of a table excerpt and a text excerpt to highlight a specific reporting discrepancy.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
140
Uses red boxes and arrows to visually connect the contradictory data points.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
141
The red box highlights the 30.4% peripheral edema rate. The text argues that the conflation of data between the P3 study and the extension study is an intentional attempt to hide worsening safety profiles.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
142
The slide uses medical definitions to frame the clinical trial results as evidence of adverse effects (edema) related to the drug DCCR.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
143
The slide uses a causal chain structure to explain the side effect.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
144
The slide uses a medical illustration to show the impact of fluid retention on heart chambers (diastolic vs systolic).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
145
The slide uses red annotations to re-interpret the company's original chart data.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
146
The slide uses a technical explanation of DEXA limitations to undermine the company's reported clinical trial results.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
147
The slide uses a table to highlight inconsistencies in clinical trial data to suggest misclassification of medical outcomes.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
148
The slide uses a table to map shared mechanisms of edema between GH and Diazoxide, and a second table to highlight the high prevalence of GH use in the P3 study.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
149
The slide uses red boxes to highlight specific text in the protocol that contradicts the lack of reporting in the final study.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
150
The slide uses a direct quote from a physician to undermine the company's marketing claims.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
151
The slide uses expert testimony to highlight a potential safety concern (edema) and suggests the company is downplaying or managing it in an unusual way.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
152
The slide uses direct quotes from a KOL to build a case against the safety of a drug (Vykat) in the PWS population.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
153
The slide uses a combination of medical argumentation and cited research conclusions to highlight the risks of a specific drug regimen.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
154
The slide uses direct quotes from pediatric endocrinologists to highlight safety concerns, specifically referencing the drug's potential to exacerbate existing cardiac risks in PWS patients.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
155
The slide uses Q&A transcripts to expose the risks associated with the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
156
This appears to be a slide from a larger activist deck, likely part of a list of grievances or evidence against a company.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
157
Uses social media follower counts as a proxy for community size to highlight the lack of engagement with the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
158
The slide highlights the discrepancy between the expected community interest and the actual low membership/activity numbers.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
159
The slide uses a specific Facebook post as a case study to contradict the product's efficacy claims.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
160
The slide uses screenshots of Facebook comments to build a case against the drug's efficacy and safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
161
The slide uses anecdotal evidence from Facebook groups to highlight negative side effects (hyperphagia, behavioral changes) associated with the drug VYKAT.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
162
The slide uses screenshots of Facebook posts to provide qualitative evidence of patient dissatisfaction and safety concerns.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
163
The slide uses direct quotes from Facebook groups to build a case against the drug's efficacy/safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
164
The slide uses screenshots of Facebook comments to illustrate the divide between frustrated participants and those defending the study.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
165
The slide uses social media screenshots to establish a pattern of adverse events.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
166
The slide uses anecdotal evidence from Facebook discussion groups to highlight potential adverse drug reactions.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
167
The slide uses screenshots of Facebook group posts to provide anecdotal evidence of drug side effects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
168
The slide uses patient testimonials to contradict the safety profile of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
169
The slide uses direct quotes from Facebook discussion groups to build a case against the drug's safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
170
The slide uses direct quotes from a Facebook discussion group to highlight a patient/caregiver pain point regarding medical monitoring.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
171
The slide uses anecdotal evidence from Facebook groups to challenge the safety profile of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
172
The slide uses anecdotal evidence from Facebook groups to challenge the safety profile of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit